JP2023512297A5 - - Google Patents
Info
- Publication number
- JP2023512297A5 JP2023512297A5 JP2022547063A JP2022547063A JP2023512297A5 JP 2023512297 A5 JP2023512297 A5 JP 2023512297A5 JP 2022547063 A JP2022547063 A JP 2022547063A JP 2022547063 A JP2022547063 A JP 2022547063A JP 2023512297 A5 JP2023512297 A5 JP 2023512297A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968999P | 2020-01-31 | 2020-01-31 | |
| US62/968,999 | 2020-01-31 | ||
| PCT/US2021/016104 WO2021155380A1 (en) | 2020-01-31 | 2021-02-01 | Bispecific t cell engagers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023512297A JP2023512297A (ja) | 2023-03-24 |
| JP2023512297A5 true JP2023512297A5 (https=) | 2024-08-15 |
| JP7840516B2 JP7840516B2 (ja) | 2026-04-06 |
Family
ID=77079996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022547063A Active JP7840516B2 (ja) | 2020-01-31 | 2021-02-01 | 二重特異性ｔ細胞エンゲージャー |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11976133B2 (https=) |
| EP (1) | EP4097135A4 (https=) |
| JP (1) | JP7840516B2 (https=) |
| KR (1) | KR20220162690A (https=) |
| CN (1) | CN115643806A (https=) |
| AU (1) | AU2021213840A1 (https=) |
| WO (1) | WO2021155380A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021008870A2 (pt) | 2019-08-12 | 2021-11-30 | Abl Bio Inc | Anticorpo, um ou mais polinucleotídeos, composição, uso do anticorpo, e, método para tratar câncer. |
| US12060434B2 (en) * | 2020-02-25 | 2024-08-13 | Gensun Biopharma Inc. | Trispecific T cell engagers |
| US12486331B2 (en) * | 2020-01-31 | 2025-12-02 | Gensun Biopharma Inc. | Bispecific T cell engagers |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| AU2023217790A1 (en) * | 2022-02-10 | 2024-08-22 | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | Bispecific antigen-binding molecule and use thereof |
| US12365743B2 (en) | 2022-02-23 | 2025-07-22 | Xencor, Inc. | Anti-CD28 x anti-PSMA antibodies |
| KR20240153575A (ko) | 2022-02-23 | 2024-10-23 | 암젠 인크 | Dll3을 표적화하는 암 치료 |
| US20250249094A1 (en) * | 2022-04-08 | 2025-08-07 | The Wistar Institute Of Anatomy And Biology | Combinations of Bispecific T cell Engagers and Methods of Use Thereof |
| WO2023204290A1 (ja) * | 2022-04-21 | 2023-10-26 | 愛知県 | 多重特異性ナノ粒子 |
| JP2025516805A (ja) * | 2022-05-20 | 2025-05-30 | アイ－エムエービー バイオファーマ ユーエス リミテッド | 固形腫瘍を治療する方法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202532431A (zh) * | 2023-09-21 | 2025-08-16 | 大陸商樂普創一生物科技（上海）有限公司 | 多特異性抗體及其用途 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025206223A1 (ja) * | 2024-03-28 | 2025-10-02 | 早智子 月田 | 抗ヒトクローディン１８．２抗体及びその使用 |
| WO2025222087A2 (en) * | 2024-04-19 | 2025-10-23 | The Brigham And Women's Hospital, Inc. | Klrb1 binding agents and methods of use thereof |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025264220A1 (en) * | 2024-06-20 | 2025-12-26 | Gensun Biopharma Inc. | Multi-specific molecules and methods of use and making thereof |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| CN120168667B (zh) * | 2025-03-18 | 2026-04-14 | 中国科学院近代物理研究所 | 一种多肽在制备dll3过度表达的肿瘤的特异性靶向分子探针中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2370467B1 (en) * | 2008-10-01 | 2016-09-07 | Amgen Research (Munich) GmbH | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| CA2894879A1 (en) * | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| CN105722859B (zh) * | 2013-07-25 | 2021-05-07 | 西托姆克斯治疗公司 | 多特异性抗体、多特异性可活化抗体及其使用方法 |
| MA41613A (fr) * | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| US20200157224A1 (en) * | 2017-06-25 | 2020-05-21 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
| MA51747A (fr) * | 2018-02-08 | 2020-12-16 | Amgen Inc | Formulation d'anticorps pharmaceutique à ph faible |
| TWI848953B (zh) * | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
-
2021
- 2021-02-01 US US17/164,699 patent/US11976133B2/en active Active
- 2021-02-01 AU AU2021213840A patent/AU2021213840A1/en active Pending
- 2021-02-01 WO PCT/US2021/016104 patent/WO2021155380A1/en not_active Ceased
- 2021-02-01 KR KR1020227029767A patent/KR20220162690A/ko active Pending
- 2021-02-01 EP EP21747803.1A patent/EP4097135A4/en active Pending
- 2021-02-01 CN CN202180026897.3A patent/CN115643806A/zh active Pending
- 2021-02-01 JP JP2022547063A patent/JP7840516B2/ja active Active